[go: up one dir, main page]

AR026163A1 - Utilizacion de retigabina para el tratamiento de dolores neuropaticos - Google Patents

Utilizacion de retigabina para el tratamiento de dolores neuropaticos

Info

Publication number
AR026163A1
AR026163A1 ARP000105028A ARP000105028A AR026163A1 AR 026163 A1 AR026163 A1 AR 026163A1 AR P000105028 A ARP000105028 A AR P000105028A AR P000105028 A ARP000105028 A AR P000105028A AR 026163 A1 AR026163 A1 AR 026163A1
Authority
AR
Argentina
Prior art keywords
retigabine
treatment
neuropatic pain
pain
neuropatic
Prior art date
Application number
ARP000105028A
Other languages
English (en)
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of AR026163A1 publication Critical patent/AR026163A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencionse refiere a la utilizacion de 2-amino-4-(4-fluorobencilamino)-1-etoxicarbonilaminobenceno de la formula I (INN:retigabina) o sus sales de utilizacion farmacéutica para la profilaxis y el tratamiento de dolores neuropáticos.
ARP000105028A 1999-09-27 2000-09-26 Utilizacion de retigabina para el tratamiento de dolores neuropaticos AR026163A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/406,135 US6117900A (en) 1999-09-27 1999-09-27 Use of retigabine for the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
AR026163A1 true AR026163A1 (es) 2003-01-29

Family

ID=23606675

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105028A AR026163A1 (es) 1999-09-27 2000-09-26 Utilizacion de retigabina para el tratamiento de dolores neuropaticos

Country Status (35)

Country Link
US (1) US6117900A (es)
EP (1) EP1223927B1 (es)
JP (1) JP2003510273A (es)
KR (1) KR100730829B1 (es)
CN (2) CN101444498A (es)
AR (1) AR026163A1 (es)
AT (1) ATE288748T1 (es)
AU (1) AU777764B2 (es)
BG (1) BG65795B1 (es)
BR (1) BR0014293A (es)
CA (2) CA2659048A1 (es)
CZ (1) CZ295980B6 (es)
DE (1) DE50009504D1 (es)
DK (1) DK1223927T3 (es)
EE (1) EE05073B1 (es)
ES (1) ES2237461T3 (es)
HK (1) HK1052471A1 (es)
HR (1) HRP20020234A2 (es)
HU (1) HUP0202853A3 (es)
IL (3) IL148309A0 (es)
IS (1) IS6303A (es)
MX (1) MXPA02003179A (es)
NO (1) NO329744B1 (es)
NZ (1) NZ517616A (es)
PL (1) PL200847B1 (es)
PT (1) PT1223927E (es)
RS (1) RS50091B (es)
RU (1) RU2264813C2 (es)
SI (1) SI1223927T1 (es)
SK (1) SK286057B6 (es)
TR (1) TR200200706T2 (es)
TW (1) TWI257304B (es)
UA (1) UA72550C2 (es)
WO (1) WO2001022953A2 (es)
ZA (1) ZA200202449B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525062B2 (en) 2000-06-09 2003-02-25 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
WO2002061075A1 (fr) * 2001-02-01 2002-08-08 Takeda Chemical Industries, Ltd. Proteine de recepteur couple aux proteines g et adn correspondant
EP1441722A2 (en) 2001-02-20 2004-08-04 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
WO2002080898A2 (en) * 2001-04-04 2002-10-17 Wyeth Methods for treating hyperactive gastric motility
US20040122008A1 (en) * 2002-09-05 2004-06-24 Protter Andrew A. Treatment of pain by inhibition of p38 MAP kinase
US20080039461A1 (en) * 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
AU2003296954A1 (en) * 2002-12-13 2004-07-09 The Regents Of The University Of California Analgesic combination comprising nalbuphine
MXPA05006463A (es) * 2002-12-27 2005-08-26 Lundbeck & Co As H Derivados de 1,2,4-triaminobenceno, utiles para tratar transtornos del sistema nervioso central.
KR20050089862A (ko) * 2002-12-27 2005-09-08 하. 룬트벡 아크티에 셀스카브 중추신경계 장애의 치료에 유용한 1,2,4-트리아미노벤젠유도체
WO2004096767A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
EP2298766B1 (en) 2005-03-03 2013-09-18 H. Lundbeck A/S Pharmaceutical formulations comrpising a substituted pyridine derivative
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
NZ575652A (en) * 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ES2375417T3 (es) * 2006-11-28 2012-02-29 Valeant Pharmaceuticals International Análogos 1,4-diamino bicíclicos de retigabina como moduladores de los canales de potasio.
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2203411B1 (en) 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
MX2011000636A (es) * 2008-07-18 2011-08-03 Valeant Pharmaceuticals Int Formulacion de liberacion modificada y metodos de uso.
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013612A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
DE102009013611A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
IT1398282B1 (it) * 2009-07-30 2013-02-22 Difass S A Ora Farmapros S P A Composizione comprendente acido alfa-lipoico e carnosina per il trattamento della sindrome dell arto fantasma
US20110087650A1 (en) * 2009-10-06 2011-04-14 Johnson Controls Technology Company Creation and use of causal relationship models in building management systems and applications
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
RU2446795C1 (ru) * 2011-03-31 2012-04-10 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения и социального развития Российской Федерации" ФГУ "МНИОИ им. П.А. Герцена "Минздравсоцразвития России" Способ предотвращения фантомного болевого синдрома после ампутации конечностей
CN102531966B (zh) * 2011-12-23 2013-07-24 山东创新药物研发有限公司 瑞替加滨的晶型d及其制备方法
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
CN103271899A (zh) * 2012-12-30 2013-09-04 北京阜康仁生物制药科技有限公司 瑞替加滨粉碎粒度在制剂中的应用
CN106176715A (zh) * 2016-06-29 2016-12-07 青岛云天生物技术有限公司 一种神经病理性疼痛治疗用药物组合物及其用途
CN105919990A (zh) * 2016-06-29 2016-09-07 青岛云天生物技术有限公司 用于预防和治疗神经病理性疼痛的药物组合物及其用途
WO2019014547A1 (en) 2017-07-14 2019-01-17 Texas Tech University System FUNCTIONALIZED PYRIDINE CARBAMATES HAVING ENHANCED NEUROPROTECTOR ACTIVITY
CN111433185A (zh) 2017-10-09 2020-07-17 拉莫特特拉维夫大学有限公司 钾离子及trpv1通道的调节剂及其用途
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
PH12022551110A1 (en) 2019-11-08 2024-02-26 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
EP4291189A1 (en) 2021-02-09 2023-12-20 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use

Also Published As

Publication number Publication date
CN101444498A (zh) 2009-06-03
SK286057B6 (sk) 2008-02-05
ATE288748T1 (de) 2005-02-15
TWI257304B (en) 2006-07-01
HK1052471A1 (zh) 2003-09-19
KR100730829B1 (ko) 2007-06-20
UA72550C2 (en) 2005-03-15
ES2237461T3 (es) 2005-08-01
PT1223927E (pt) 2005-06-30
CA2659048A1 (en) 2001-04-05
EE05073B1 (et) 2008-10-15
JP2003510273A (ja) 2003-03-18
RU2264813C2 (ru) 2005-11-27
IL187030A (en) 2011-06-30
CA2384504A1 (en) 2001-04-05
PL353393A1 (en) 2003-11-17
NO20021418D0 (no) 2002-03-21
CN1409632A (zh) 2003-04-09
WO2001022953A3 (de) 2002-05-23
WO2001022953A2 (de) 2001-04-05
DE50009504D1 (de) 2005-03-17
CZ295980B6 (cs) 2005-12-14
PL200847B1 (pl) 2009-02-27
SK2922002A3 (en) 2002-08-06
US6117900A (en) 2000-09-12
CN100522155C (zh) 2009-08-05
KR20020042691A (ko) 2002-06-05
IS6303A (is) 2002-03-18
HUP0202853A2 (hu) 2002-12-28
IL148309A0 (en) 2002-09-12
ZA200202449B (en) 2003-03-26
EP1223927B1 (de) 2005-02-09
BG106450A (en) 2002-09-30
CA2384504C (en) 2009-05-26
DK1223927T3 (da) 2005-04-11
IL148309A (en) 2007-12-03
EP1223927A2 (de) 2002-07-24
EE200200145A (et) 2003-04-15
HRP20020234A2 (en) 2003-06-30
SI1223927T1 (es) 2005-08-31
NZ517616A (en) 2002-12-20
BG65795B1 (bg) 2009-12-31
MXPA02003179A (es) 2003-08-20
RS50091B (sr) 2009-01-22
NO20021418L (no) 2002-03-21
HUP0202853A3 (en) 2003-10-28
IL187030A0 (en) 2008-02-09
BR0014293A (pt) 2002-05-21
TR200200706T2 (tr) 2002-10-21
AU777764B2 (en) 2004-10-28
CZ2002989A3 (cs) 2002-08-14
AU7906100A (en) 2001-04-30
YU20302A (sh) 2005-03-15
RU2002109240A (ru) 2004-01-10
NO329744B1 (no) 2010-12-13

Similar Documents

Publication Publication Date Title
AR026163A1 (es) Utilizacion de retigabina para el tratamiento de dolores neuropaticos
BRPI0411900A (pt) compostos antivirais e métodos
BR0010555A (pt) Inibidores de neuraminidases
BRPI0412763A (pt) formas anidras, hidratadas ou solvatadas de um composto, forma cristalina, composição farmacêutica, e, método para o tratamento ou a profilaxia de distúrbios
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
BR9805544A (pt) Uso de um composto.
PT1259512E (pt) Compostos de pteridin para o tratamento da psoriase
BRPI0417101A (pt) uso de compostos de peptìdeo para tratamento de dor neuropática central
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
PT1392292E (pt) Piranoindazoles e sua utilizacao para o tratamento de glaucoma
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
HN2002000110A (es) Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
SV2003000741A (es) Compuesto lactamico x-13170
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
CY1109975T1 (el) Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων
SE9801494D0 (sv) Novel use
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
BR0315055A (pt) Diamidas de ácido pirimidin-4,6-dicarboxìilco para a inibição seletiva de colagenases
BRPI0508807A (pt) composição de tratamento capilar, uso de uma composição e método de tratamento de cabelo
PT1276495E (pt) Utilizacao de tensioactivo pulmonar recombinante para o tratamento precoce de doencas pulmonares agudas
BRPI0409586A (pt) ácidos hidroxámicos úteis no tratamento de distúrbios hiperproliferativos

Legal Events

Date Code Title Description
FB Suspension of granting procedure